BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC Full data will be presented at the 2023 ASCO Genitourinary Can...
United States Vincentj Oneill Bioxcel Therapeutics Inc Aggressive Form Rare Prostate Cancers Symposium
Source: pharmiweb.com